Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Carole Diane Mitnick, Sc.D.

Co-Author

This page shows the publications co-authored by Carole Mitnick and Kwonjune Seung.
Connection Strength

4.017
  1. Culture Conversion at 6 Months in Patients Receiving Delamanid-containing Regimens for the Treatment of Multidrug-resistant Tuberculosis. Clin Infect Dis. 2020 07 11; 71(2):415-418.
    View in: PubMed
    Score: 0.883
  2. Salvage therapy for multidrug-resistant tuberculosis. Clin Microbiol Infect. 2014 May; 20(5):441-6.
    View in: PubMed
    Score: 0.549
  3. All-oral longer regimens are effective for the management of multidrug-resistant tuberculosis in high-burden settings. Eur Respir J. 2022 01; 59(1).
    View in: PubMed
    Score: 0.246
  4. Evaluating newly approved drugs for multidrug-resistant tuberculosis (endTB): study protocol for an adaptive, multi-country randomized controlled trial. Trials. 2021 Sep 25; 22(1):651.
    View in: PubMed
    Score: 0.240
  5. INCIDENCE OF HIGH GRADE QTCF PROLONGATION AND ITS MANAGEMENT AMONG PATIENTS UNDERGOING TREATMENT FOR DRUG RESISTANT TUBERCULOSIS (DR-TB): CASE SERIES. Afr J Infect Dis. 2021; 15(2 Suppl):38-41.
    View in: PubMed
    Score: 0.239
  6. Culture Conversion in Patients Treated with Bedaquiline and/or Delamanid. A Prospective Multicountry Study. Am J Respir Crit Care Med. 2021 01 01; 203(1):111-119.
    View in: PubMed
    Score: 0.228
  7. Introducing new and repurposed TB drugs: the endTB experience. Int J Tuberc Lung Dis. 2020 10 01; 24(10):1081-1086.
    View in: PubMed
    Score: 0.224
  8. High prevalence of hepatitis C infection among multidrug-resistant tuberculosis patients. J Hepatol. 2020 05; 72(5):1028-1029.
    View in: PubMed
    Score: 0.216
  9. The endTB observational study protocol: treatment of MDR-TB with bedaquiline or delamanid containing regimens. BMC Infect Dis. 2019 Aug 20; 19(1):733.
    View in: PubMed
    Score: 0.208
  10. Efficacy and Safety of High-Dose Rifampin in Pulmonary Tuberculosis. A Randomized Controlled Trial. Am J Respir Crit Care Med. 2018 09 01; 198(5):657-666.
    View in: PubMed
    Score: 0.194
  11. Evaluation of high-dose rifampin in patients with new, smear-positive tuberculosis (HIRIF): study protocol for a randomized controlled trial. BMC Infect Dis. 2016 08 27; 16(1):453.
    View in: PubMed
    Score: 0.169
  12. Aggressive regimens for multidrug-resistant tuberculosis decrease all-cause mortality. PLoS One. 2013; 8(3):e58664.
    View in: PubMed
    Score: 0.133
  13. Comprehensive treatment of extensively drug-resistant tuberculosis. N Engl J Med. 2008 Aug 07; 359(6):563-74.
    View in: PubMed
    Score: 0.097
  14. Self-administered, standardized regimens for multidrug-resistant tuberculosis in South Korea. Int J Tuberc Lung Dis. 2004 Mar; 8(3):361-8.
    View in: PubMed
    Score: 0.071
  15. Safety and effectiveness outcomes from a 14-country cohort of patients with multi-drug resistant tuberculosis treated concomitantly with bedaquiline, delamanid and other second-line drugs. Clin Infect Dis. 2022 Mar 04.
    View in: PubMed
    Score: 0.062
  16. Safety of treatment regimens containing bedaquiline and delamanid in the endTB cohort. Clin Infect Dis. 2022 Jan 13.
    View in: PubMed
    Score: 0.061
  17. Setting up pharmacovigilance based on available endTB Project data for bedaquiline. Int J Tuberc Lung Dis. 2020 10 01; 24(10):1087-1094.
    View in: PubMed
    Score: 0.056
  18. Treatment correlates of successful outcomes in pulmonary multidrug-resistant tuberculosis: an individual patient data meta-analysis. Lancet. 2018 09 08; 392(10150):821-834.
    View in: PubMed
    Score: 0.049
  19. Surgery as an Adjunctive Treatment for Multidrug-Resistant Tuberculosis: An Individual Patient Data Metaanalysis. Clin Infect Dis. 2016 Apr 01; 62(7):887-895.
    View in: PubMed
    Score: 0.040
  20. Multidrug resistant pulmonary tuberculosis treatment regimens and patient outcomes: an individual patient data meta-analysis of 9,153 patients. PLoS Med. 2012; 9(8):e1001300.
    View in: PubMed
    Score: 0.032
  21. Representative drug susceptibility patterns for guiding design of retreatment regimens for MDR-TB. Int J Tuberc Lung Dis. 2006 Mar; 10(3):290-6.
    View in: PubMed
    Score: 0.020
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.